[Form 4] Cue Biopharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Cue Biopharma, Inc. (CUE) reported an equity award to its chief development officer. The reporting person received a stock option covering 50,000 shares of common stock at an exercise price of $0.72 per share on 09/29/2025. This option is scheduled to become fully exercisable on the first anniversary of the grant date and carries an expiration date of 09/28/2035. After this grant, the reporting person holds 50,000 derivative securities related to Cue Biopharma common stock with direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baker Daniel G.

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF DEVELOPMENT OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.72	09/29/2025		A		50,000		(1)	09/28/2035	Common Stock	50,000	$0.0	50,000	D

Explanation of Responses:

1. This stock option becomes fully exercisable on the first anniversary of the grant date.

	/s/ Daniel G. Baker by Colin Sandercock, attorney-in-fact	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Cue Biopharma (CUE) disclose in this Form 4 filing?

Cue Biopharma disclosed that its chief development officer received a stock option for 50,000 shares of common stock at an exercise price of $0.72 per share, granted on 09/29/2025.

Who is the reporting person in Cue Biopharma (CUE)'s Form 4?

The reporting person is Daniel G. Baker, who serves as Cue Biopharma's chief development officer and filed the form as an individual reporting person.

How many Cue Biopharma (CUE) stock options were granted and at what price?

The award consists of a stock option to purchase 50,000 shares of Cue Biopharma common stock at an exercise price of $0.72 per share.

When do the newly granted Cue Biopharma (CUE) stock options vest and expire?

According to the disclosure, the stock option becomes fully exercisable on the first anniversary of the 09/29/2025 grant date and has an expiration date of 09/28/2035.

What type of ownership does the reporting person have in these Cue Biopharma (CUE) options?

The reporting person holds 50,000 derivative securities related to Cue Biopharma common stock with direct ownership after the reported transaction.

Does this Form 4 involve derivative or non-derivative Cue Biopharma (CUE) securities?

The reported transaction involves derivative securities, specifically a stock option (right to buy) Cue Biopharma common stock.